- Details
- In an abstract review session at the 2021 ASCO annual meeting, Lisa Horvath, PhD, MBBS, FRACP, reviewed 3 abstracts: PEACE-1, the SWOG S1216 trial, and the PEACE-III trial. She expanded her conversation about these three abstracts in a discussion with Alicia Morgans, MD, MPH. In the primary conversation about the PEACE-1 trial, Dr. Horvath discussed the main interest, in this phase III trial, to b...
|
- Details
- The SWOG S1216 is a Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Tak is an oral selective nonsteroidal 17, 20-lyase inhibitor that blocks the synthesis of gonadal and adrenal androgens and in this trial the clinical benefit of Tak wi...
|
- Details
- In a conversation with Alicia Morgans on clinical characteristics of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and identifying subsets of patients to improve personalized treatments, Christopher Sweeney shares data from a European Urology publication Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androge...
|
- Details
- In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi presented the first results of the PEACE-1 trial. PEACE-1 is a phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer. Adding abiraterone to ADT + docetaxel significantly impro...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Drs Scott Tagawa and Stephen Freedland highlight real-world evidence of survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the Veterans Health Administration system. Drs. Tagawa, Freedland, and colleagues used the Veterans Health Administration claims data to identify patients with mCSPC who initiated ADT...
|
- Details
- Matthew Deek and Phuoc Tran join Charles Ryan to discuss their recent paper "The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited" published in European Urology. The aim of this study was to characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biologi...
|
- Details
- Alicia Morgans, MD, MPH presents a State of Art Lecture on treatment selection for mCRPC patients who have disease progression progressing after combination treatment for in metastatic castration-sensitive prostate cancer (mCSPC). The learning objectives of this presentation include to understand the rationale for avoiding sequencing of androgen receptor-targeted agents one after another, how to c...
|
- Details
- Michael Morris, MD, and Christopher Sweeney, MBBS join Alicia Morgans, MD, MPH in a discussion on the treatment of metastatic hormone-sensitive prostate cancer. Dr. Sweeney shares his perspective on the use of combination therapy, in addition to traditional ADT, and how he approaches treatment decisions Dr. Morris discusses the latest data in this space coming from the CHAARTED and STAMPEDE studie...
|
- Details
- Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...
|
- Details
- Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to imp...
|
